Company Overview

Innate Immunotherapeutics is an Australian medical biotechnology company advancing the development of drugs that inhibit Focal Adhesion Kinase (FAK).  FAK is fast becoming an important target in hard to treat cancers where tumours use FAK to build a protective wall to shield against the onslaught of the immune system.  FAK is also implicated in a number of chronic fibrotic diseases.

The Company has two FAK inhibiting drug candidates which are being initially positioned for clinical development targeting pancreatic cancer, high grade serous ovarian cancer, and idiopathic pulmonary fibrosis.

Innate Immunotherapeutics is a public company traded on the Australian Securities Exchange (ASX Code: IIL).